An observational study in Dysentery Amebic, sponsored by Sohag University. Status unknown at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2021-10-12.
Sponsored by Sohag University · Observational
Amoebiasis, an infection by the protozoan parasite Entamoeba histolytica is globally considered as the third leading parasitic cause of human mortality besides malaria and schistosomiasis. It is estimated that E. histolytica may infect half a billion people annually. Moreover, it was estimated that 100,000 patients per year died due to the clinical complications of the disease. Laboratory diagnosis of E. histolytica/dispar is usually achieved by microscopic detection of trophozoites or cysts in stool samples. Microscopy is time consuming and requires an experienced observer to identify the organism. Furthermore, it must be performed on three stool samples to increase sensitivity leading to decreased patient compliance and delay in the final diagnosis. Therefore, a few the commercially available copro-antigen assay have been developed for E. histolytica/dispar diagnosis including the enzyme immunoassay and non-enzymatic immunochromatographic (ICT) assays that do not depend on microscopy skills and increase laboratory efficiency by reducing time and cost.
The aim of the study is:
44 studies on the registry are indexed under Dysentery; 6 are open to participants now.
Browse Dysentery studies →Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.
Counted across the registry records on this site, refreshed daily.
samples will be collected from outpatients complaining of dysentery or diarrhea with any age \& sex groups from different locations (cities and village).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
evaluate the efficacy of immunochromatographic Copro-antigen assay for diagnosis of Entamoeba histolytica/ dispar.
comparing the sensitivity and specifity with conventional microscopy for diagnosis of Entamoeba histolytica/ dispar infection.
Time frame: 16 weeks following the startpoint of the study.
detect the prevelance of Entamoeba histolytica/ dispar in Sohag.
By examining stool samples from 100 patients, the number of cases with Entamoena histolytica/dispar infection is recorded.
Time frame: 16 weeks following the startpoint of the study.
Plan to share: Undecided — undecided
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Oct 2021, 7 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.